Table 3.
Adjusted Hazard Ratios Among Adults With Diabetes (N=8407) Comparing Time to Remission Since Surgery and Time to Relapse Since Remission for Gastric Bypass and Sleeve Gastrectomy, Stratified by Baseline Depression Status
| Estimated Cumulative Percentage of Patients With T2DM Who Had Experienced an Initial Remission (95% CI) at Different Times of Follow-up | ||||||
|---|---|---|---|---|---|---|
| T2DM Remission | Adjusted HR* (95% CI) | P-value | 1 yr | 3 yr | 5 yr | |
| RYGB vs SG - No Depression | 1.09 (1.02, 1.15) | 0.025 | RYGB | 63.3 (61.5, 65.0) | 86.4 (85.0, 87.7) | 88.0 (86.6, 89.3) |
| SG | 60.3 (58.0, 62.5) | 84.1 (82.1, 85.8) | 85.8 (83.9, 87.5) | |||
| RYGB vs SG - Depression | 1.12 (1.03, 1.23) | 0.028 | RYGB | 61.1 (58.7, 63.3) | 84.7 (82.8, 86.4) | 86.4 (84.5, 88.1) |
| SG | 56.8 (53.3, 60.0) | 81.2 (78.1, 83.8) | 83.1 (80.0, 85.6) | |||
| Interaction P-Value = | 0.571 | |||||
| Estimated Cumulative Percentage of Patients With Initial T2DM Remission Who Had Experienced Relapse (95% CI) at Different Times of Follow-up | ||||||
| T2DM Remission | Adjusted HR† (95% CI) | P-value | 1 yr | 3 yr | 5 yr | |
| RYGB vs SG – No Depression | 0.77 (0.68, 0.87) | <0.001 | RYGB | 9.1 (8.0, 10.1) | 23.7 (21.3, 26.0) | 37.2 (33.3, 40.9) |
| SG | 11.7 (10.1, 13.2) | 29.6 (26.2, 32.9) | 45.4 (40.1, 50.2) | |||
| RYGB vs SG – Depression | 0.67 (0.56, 0.80) | <0.001 | RYGB | 8.0 (6.9, 9.2) | 21.1 (18.4, 23.8) | 33.6 (29.1, 37.8) |
| SG | 11.8 (9.6, 13.9) | 29.8 (24.9, 34.4) | 45.7 (38.5, 52.0) | |||
| Interaction P-value = | 0.282 | |||||
Remission of diabetes defined as HbAlc <6.5% after б months without any prescription order for a diabetes medication; Covariates included: age, sex, race, Hispanic ethnicity, BMI, HbA1c, blood pressure, days from BMI measurement to baseline, number of inpatient hospital days in the year before surgery, number of diabetes medications excluding insulin, insulin use, Charlson/Elixhauser comorbidity score, year of procedure, having a code for diabetes, smoking, having a code for other comorbidities (hypertension, dyslipidemia, sleep apnea, osteoarthritis, NAFLD, GERD, depression, anxiety, eating disorder, substance use, psychosis, kidney disease, infertility, polycystic ovaries, deep vein thrombosis, pulmonary embolism), having codes for specific diabetes medications (biguanides, GLP-1 agonists, sulfonylureas, thiazolidinediones, and other) and site.
Relapse of diabetes defined as occurrence of any HbA1c ≥6.5% and/or prescription order for a diabetes medication Covariates included: age, sex, race, Hispanic ethnicity, BMI, HbA1c, blood pressure, days from BMI measurement to baseline, number of in patient hospital days in the year before surgery, number of diabetes medications excluding insulin, insulin use, Charlson/Elixhauser comorbidity score, year of procedure, having a code for diabetes, smoking, having a code for other comorbidities (hypertension, dyslipidemia, sleep apnea, osteoarthritis, NAFLD, GERD, depression, anxiety, eating disorder, substance use, psychosis, kidney disease, infertility, polycystic ovaries, deep vein thrombosis, pulmonary embolism), having codes for specific diabetes medications (biguanides, GLP-1 agonists, sulfonylureas, thiazolidinediones, and other) and site.
CI, Confidence interval; HR, hazard ratios; RYGB, Roux-en-Y gastric bypass; SG, Sleeve gastrectomy.